Does V600E BRAF mutation predict vinorelbine efficacy? A proof-of-concept from a lung micropapillary adenocarcinoma metastatic to the breast

Pathologica. 2017 Dec;109(4):426-428.

Abstract

BRAF mutations occur in about 3% of all lung adenocarcinomas and V600E missense mutation characterizes about half of BRAF-mutated lung adenocarcinomas and is significantly associated with micropapillary pattern and shorter disease-free and overall survival rates. In this report, we report a challenging case of a patient with a metastatic micropapillary adenocarcinoma of the lung harbouring V600E BRAF mutation who experienced a surprising protracted clinical response to metronomic vinorelbine. The possible association between the V600E BRAF mutation pathway and the effective use of vinca alkaloid is discussed.

Keywords: Adenocarcinoma; BRAF; Breast; Lung; Metastasis; Micropapillary; V600E; Vinorelbine.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma of Lung / diagnosis*
  • Adenocarcinoma of Lung / genetics
  • Adenocarcinoma of Lung / secondary
  • Aged, 80 and over
  • Antineoplastic Agents, Phytogenic / pharmacology
  • Breast / pathology
  • Breast Neoplasms / diagnosis*
  • Breast Neoplasms / genetics
  • Breast Neoplasms / secondary
  • Female
  • Humans
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Mutation, Missense
  • Neoplasm Metastasis
  • Proto-Oncogene Proteins B-raf / genetics*
  • Vinorelbine / pharmacology

Substances

  • Antineoplastic Agents, Phytogenic
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • Vinorelbine